Literature DB >> 29589281

Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group (TCCSG) Study L04-16.

Hiroyuki Takahashi1, Ryosuke Kajiwara2, Motohiro Kato3, Daisuke Hasegawa4, Daisuke Tomizawa3, Yasushi Noguchi5, Kazutoshi Koike6, Daisuke Toyama7, Hiromasa Yabe8, Michiko Kajiwara9, Junya Fujimura10, Manabu Sotomatsu11, Setsuo Ota12, Miho Maeda13, Hiroaki Goto14, Yoko Kato15, Tetsuya Mori16, Takeshi Inukai17, Hiroyuki Shimada18, Keitaro Fukushima19, Chitose Ogawa20, Atsushi Makimoto21, Takashi Fukushima22, Kentaro Ohki23, Katsuyoshi Koh24, Nobutaka Kiyokawa23, Atsushi Manabe4, Akira Ohara25.   

Abstract

The survival rate of children with acute lymphoblastic leukemia (ALL) has increased to approximately 90% after substantial progress in risk-oriented treatment strategies. Between 2005 and 2013, the Tokyo Children's Cancer Study Group (TCCSG) conducted a risk-oriented, non-randomized study, L04-16. The principal aim of this study was to assemble background characteristics and treatment outcomes, and gather genetic information on leukemic cells under central diagnosis. This report outlines the background characteristics and treatment outcomes of 1033 children with ALL treated according to a TCCSG platform. The 5-year event-free and overall survival (OS) rates for all children were 78.1 ± 1.3 and 89.6 ± 1.0%, respectively. The OS rate was significantly higher in children with B-cell precursor (BCP)-ALL (91.9 ± 1.0%, n = 916) than in those with T-ALL (71.9 ± 4.3%, n = 117, p < 0.001). In univariate analysis for BCP-ALL, children aged 1-6 years (5y-OS: 94.2 ± 1.0%), with an initial white blood cell count of < 20,000/μL (94.0 ± 1.0%), high hyperdiploidy (95.4 ± 1.6%), ETV6-RUNX1 (97.4 ± 1.2%) or TCF3-PBX1 (96.9 ± 2.1%), and "Day8NoBlasts" (96.4 ± 1.1%) had the best outcomes. Genetic investigation revealed two novel fusion genes within this cohort: ETV6-ZNF385A and ZNF362-TCF4. Our study highlighted the clinical aspects of genomic features of ALL in Japanese children. We provide fundamental information for the further molecular investigation of this disease.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Childhood leukemia; Clinical trial; Novel fusion genes

Mesh：

Substances：

Year:  2018        PMID： 29589281     DOI： 10.1007/s12185-018-2440-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  28 in total

Review 1.  Biology, risk stratification, and therapy of pediatric acute leukemias: an update.

Authors:  Ching-Hon Pui; William L Carroll; Soheil Meshinchi; Robert J Arceci
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

2.  Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia.

Authors:  Yoichi Tanaka; Motohiro Kato; Daisuke Hasegawa; Kevin Y Urayama; Hisaya Nakadate; Kensuke Kondoh; Kozue Nakamura; Katsuyoshi Koh; Takako Komiyama; Atsushi Manabe
Journal:  Br J Haematol       Date:  2015-06-02       Impact factor: 6.998

3.  ATF7IP as a novel PDGFRB fusion partner in acute lymphoblastic leukaemia in children.

Authors:  Kenichiro Kobayashi; Kazumasa Mitsui; Hitoshi Ichikawa; Kazuhiko Nakabayashi; Masaki Matsuoka; Yasuko Kojima; Hiroyuki Takahashi; Kazutoshi Iijima; Kaori Ootsubo; Keisuke Oboki; Hajime Okita; Kazuki Yasuda; Hiromi Sakamoto; Kenichiro Hata; Teruhiko Yoshida; Kenji Matsumoto; Nobutaka Kiyokawa; Akira Ohara
Journal:  Br J Haematol       Date:  2014-03-15       Impact factor: 6.998

4.  Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.

Authors:  Ching-Hon Pui; Deqing Pei; Elaine Coustan-Smith; Sima Jeha; Cheng Cheng; W Paul Bowman; John T Sandlund; Raul C Ribeiro; Jeffrey E Rubnitz; Hiroto Inaba; Deepa Bhojwani; Tanja A Gruber; Wing H Leung; James R Downing; William E Evans; Mary V Relling; Dario Campana
Journal:  Lancet Oncol       Date:  2015-03-20       Impact factor: 41.316

5.  Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.

Authors:  Anja Möricke; Alfred Reiter; Martin Zimmermann; Helmut Gadner; Martin Stanulla; Michael Dördelmann; Lutz Löning; Rita Beier; Wolf-Dieter Ludwig; Richard Ratei; Jochen Harbott; Joachim Boos; Georg Mann; Felix Niggli; Andreas Feldges; Günter Henze; Karl Welte; Jörn-Dirk Beck; Thomas Klingebiel; Charlotte Niemeyer; Felix Zintl; Udo Bode; Christian Urban; Helmut Wehinger; Dietrich Niethammer; Hansjörg Riehm; Martin Schrappe
Journal:  Blood       Date:  2008-02-19       Impact factor: 22.113

6.  Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.

Authors:  M Smith; D Arthur; B Camitta; A J Carroll; W Crist; P Gaynon; R Gelber; N Heerema; E L Korn; M Link; S Murphy; C H Pui; J Pullen; G Reamon; S E Sallan; H Sather; J Shuster; R Simon; M Trigg; D Tubergen; F Uckun; R Ungerleider
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

7.  Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232.

Authors:  Eric C Larsen; Meenakshi Devidas; Si Chen; Wanda L Salzer; Elizabeth A Raetz; Mignon L Loh; Leonard A Mattano; Catherine Cole; Alisa Eicher; Maureen Haugan; Mark Sorenson; Nyla A Heerema; Andrew A Carroll; Julie M Gastier-Foster; Michael J Borowitz; Brent L Wood; Cheryl L Willman; Naomi J Winick; Stephen P Hunger; William L Carroll
Journal:  J Clin Oncol       Date:  2016-04-25       Impact factor: 44.544

Review 8.  Relapsed childhood acute lymphoblastic leukaemia.

Authors:  Deepa Bhojwani; Ching-Hon Pui
Journal:  Lancet Oncol       Date:  2013-05       Impact factor: 41.316

9.  Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia.

Authors:  K Koh; D Tomizawa; A Moriya Saito; T Watanabe; T Miyamura; M Hirayama; Y Takahashi; A Ogawa; K Kato; K Sugita; T Sato; T Deguchi; Y Hayashi; J Takita; Y Takeshita; M Tsurusawa; K Horibe; S Mizutani; E Ishii
Journal:  Leukemia       Date:  2014-06-03       Impact factor: 11.528

10.  Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph(+) ALL04.

Authors:  Atsushi Manabe; Hirohide Kawasaki; Hiroyuki Shimada; Itaru Kato; Yuichi Kodama; Atsushi Sato; Kimikazu Matsumoto; Keisuke Kato; Hiromasa Yabe; Kazuko Kudo; Motohiro Kato; Tomohiro Saito; Akiko M Saito; Masahito Tsurusawa; Keizo Horibe
Journal:  Cancer Med       Date:  2015-01-31       Impact factor: 4.452
View more
  14 in total

1.  Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases.

Authors:  Jian-Feng Li; Yu-Ting Dai; Henrik Lilljebjörn; Shu-Hong Shen; Bo-Wen Cui; Ling Bai; Yuan-Fang Liu; Mao-Xiang Qian; Yasuo Kubota; Hitoshi Kiyoi; Itaru Matsumura; Yasushi Miyazaki; Linda Olsson; Ah Moy Tan; Hany Ariffin; Jing Chen; Junko Takita; Takahiko Yasuda; Hiroyuki Mano; Bertil Johansson; Jun J Yang; Allen Eng-Juh Yeoh; Fumihiko Hayakawa; Zhu Chen; Ching-Hon Pui; Thoas Fioretos; Sai-Juan Chen; Jin-Yan Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-28       Impact factor: 11.205

2.  Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis.

Authors:  Linhui Hu; Alice Charwudzi; Qian Li; Weiwei Zhu; Qianshan Tao; Shudao Xiong; Zhimin Zhai
Journal:  Ann Hematol       Date:  2021-02-15       Impact factor: 3.673

Review 3.  Hyperdiploidy: the longest known, most prevalent, and most enigmatic form of acute lymphoblastic leukemia in children.

Authors:  Oskar A Haas; Arndt Borkhardt
Journal:  Leukemia       Date:  2022-10-20       Impact factor: 12.883

4.  Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia.

Authors:  Hiroo Ueno; Kenichi Yoshida; Yusuke Shiozawa; Yasuhito Nannya; Yuka Iijima-Yamashita; Nobutaka Kiyokawa; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Tomoya Isobe; Masafumi Seki; Shunsuke Kimura; Hideki Makishima; Masahiro M Nakagawa; Nobuyuki Kakiuchi; Keisuke Kataoka; Tetsuichi Yoshizato; Dai Nishijima; Takao Deguchi; Kentaro Ohki; Atsushi Sato; Hiroyuki Takahashi; Yoshiko Hashii; Sadao Tokimasa; Junichi Hara; Yoshiyuki Kosaka; Koji Kato; Takeshi Inukai; Junko Takita; Toshihiko Imamura; Satoru Miyano; Atsushi Manabe; Keizo Horibe; Seishi Ogawa; Masashi Sanada
Journal:  Blood Adv       Date:  2020-10-27

5.  New anti-IL-7Rα monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models.

Authors:  Julie A Hixon; Caroline Andrews; Lila Kashi; Casey L Kohnhorst; Emilee Senkevitch; Kelli Czarra; Joao T Barata; Wenqing Li; Joel P Schneider; Scott T R Walsh; Scott K Durum
Journal:  Leukemia       Date:  2019-08-22       Impact factor: 11.528

6.  Hirsutanol A inhibits T-acute lymphocytic leukemia Jurkat cell viability through cell cycle arrest and p53-dependent induction of apoptosis.

Authors:  Fangfang Zhong; You Yang; Danwei Ren; Sili Long; Xiang Qin; Jing Liu; Yan Zeng; Wenjian Lan; Wenzhe Ma; Wenjun Liu
Journal:  Exp Ther Med       Date:  2021-05-11       Impact factor: 2.447

7.  Clinical and molecular characteristics of MEF2D fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in MEF2D-HNRNPH1 gene fusion.

Authors:  Kentaro Ohki; Nobutaka Kiyokawa; Yuya Saito; Shinsuke Hirabayashi; Kazuhiko Nakabayashi; Hitoshi Ichikawa; Yukihide Momozawa; Kohji Okamura; Ai Yoshimi; Hiroko Ogata-Kawata; Hiromi Sakamoto; Motohiro Kato; Keitaro Fukushima; Daisuke Hasegawa; Hiroko Fukushima; Masako Imai; Ryosuke Kajiwara; Takashi Koike; Isao Komori; Atsushi Matsui; Makiko Mori; Koichi Moriwaki; Yasushi Noguchi; Myoung-Ja Park; Takahiro Ueda; Shohei Yamamoto; Koichi Matsuda; Teruhiko Yoshida; Kenji Matsumoto; Kenichiro Hata; Michiaki Kubo; Yoichi Matsubara; Hiroyuki Takahashi; Takashi Fukushima; Yasuhide Hayashi; Katsuyoshi Koh; Atsushi Manabe; Akira Ohara
Journal:  Haematologica       Date:  2018-08-31       Impact factor: 9.941

8.  Resistance of t(17;19)-acute lymphoblastic leukemia cell lines to multiagents in induction therapy.

Authors:  Atsushi Watanabe; Takeshi Inukai; Keiko Kagami; Masako Abe; Masatoshi Takagi; Takashi Fukushima; Hiroko Fukushima; Toru Nanmoku; Kiminori Terui; Tatsuya Ito; Tsutomu Toki; Etsuro Ito; Junya Fujimura; Hiroaki Goto; Mikiya Endo; Thomas Look; Mark Kamps; Masayoshi Minegishi; Junko Takita; Toshiya Inaba; Hiroyuki Takahashi; Akira Ohara; Daisuke Harama; Tamao Shinohara; Shinpei Somazu; Hiroko Oshiro; Koshi Akahane; Kumiko Goi; Kanji Sugita
Journal:  Cancer Med       Date:  2019-07-15       Impact factor: 4.452

9.  Invasive Fungal Diseases in Children with Acute Leukemia and Severe Aplastic Anemia.

Authors:  Sutatta Supatharawanich; Nattee Narkbunnam; Nassawee Vathana; Chayamon Takpradit; Kamon Phuakpet; Bunchoo Pongtanakul; Sasima Tongsai; Phakatip Sinlapamongkolkul; Popchai Ngamskulrungroj; Wanatpreeya Phongsamart; Kleebsabai Sanpakit; Jassada Buaboonnam
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-07-01       Impact factor: 2.576

Review 10.  Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia.

Authors:  Seth E Karol; Ching-Hon Pui
Journal:  Ther Adv Hematol       Date:  2020-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.